This retrospective study investigated the impact of rifaximin-α for secondary prevention of OHE on hospital resource utilisation using real world data from 7 UK centres.
1
Estimated annual inpatient admission and rifaximin-α costs
UK/XIF5/0719/0523 DOP: October 2019